Cell Therapy and Regenerative Medicine at TCVGH
Center Overview
Our team specializes in cancer, autoimmune diseases, neurological disorders, and degenerative joint diseases. Currently, the CTRMC focuses on cancer, cerebral palsy, idiopathic pulmonary fibrosis, refractory lupus erythematosus, hypoxic encephalopathy, and other difficult-to-treat diseases.
In addition to providing cell therapy, we also offer a range of interdisciplinary services to bring patients the most comprehensive health care.Our mission is to translate stem cells and cancer-fighting cells from the bench to bedside, providing new treatment options for patients with cancer or chronic diseases who have failed conventional therapies. We have established in-house teams of scientists and clinicians to build new cell processing laboratories and a cGMP cell manufacturing facility, enabling the development of clinical-grade novel cell products in collaboration with universities and industry.
Services & Treatment
We provide integrated multidisciplinary care in cell therapy and immunotherapy.
- A variety of adoptive cell therapies for cancer patients, including CIK cells, NK cells, DC cells, and DC-CIK cells.
- Chimeric Antigen Receptor T cell (CAR-T) therapy for refractory and relapsed acute B-cell leukemia and lymphoma.
- Adipose-derived mesenchymal stem cells (ADSCs) for the treatment of osteoarthritis and knee cartilage defects.
- Bone marrow-derived mesenchymal stem cells (BMSCs) for the treatment of spinal cord injury.
Clinical Trials
- Allogenic mesenchymal stem cells for Cerebral palsy
- Allogenic mesenchymal stem cells for Idiopathic pulmonary fibrosis
- VEGF-engineered mesenchymal stem cells for Critical limb ischemia.
- Anti-CD3 / anti-EGFR bispecific antibody-armed T cells for metastatic colorectal cancer .
- Adoptive memory T cell therapy for hepatocellular carcinoma.
- NY-eso-1 TCR-T therapy for solid tumors.
- Chimeric Antigen Receptor T cells (CAR-T) Therapy for refractory systemic lupus erythrematosus.
- Chimeric Antigen Receptor T cells (CAR-T) Therapy for refractory lymphoma.
TAIWAN TCVGH Research Building R208
Tel +886-4-23592525 # 3998
2025/10/14 17:00:57
2361
分享
首長信箱
分享
